Published in Nephron Clin Pract on April 22, 2010
Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy? | NCT02900170
Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int (2011) 4.51
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con. Clin J Am Soc Nephrol (2016) 1.23
Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation. J Am Soc Nephrol (2011) 1.17
5/6 nephrectomy as a validated rat model mimicking human warfarin-related nephropathy. Am J Nephrol (2012) 1.10
The occurrence of warfarin-related nephropathy and effects on renal and patient outcomes in korean patients. PLoS One (2013) 0.97
Warfarin-related nephropathy in a patient with mild IgA nephropathy on dabigatran and aspirin. Clin Kidney J (2013) 0.89
Warfarin-related nephropathy: possible role for the warfarin pharmacogenetic profile. Clin Kidney J (2014) 0.85
The emerging threat of superwarfarins: history, detection, mechanisms, and countermeasures. Ann N Y Acad Sci (2016) 0.83
Anticoagulants and acute kidney injury: clinical and pathology considerations. Kidney Res Clin Pract (2014) 0.82
Pathogenesis of glomerular haematuria. World J Nephrol (2015) 0.81
Differential diagnosis of glomerular disease: a systematic and inclusive approach. Am J Nephrol (2013) 0.81
Correlates and outcomes of warfarin initiation in kidney transplant recipients newly diagnosed with atrial fibrillation. Nephrol Dial Transplant (2014) 0.75
Warfarin related acute kidney injury: A case report. Indian J Nephrol (2017) 0.75
Warfarin related nephropathy: a case report and review of the literature. BMC Nephrol (2016) 0.75
Acute kidney injury due to glomerular haematuria and obstructive erythrocyte casts associated with thrombocytopaenia and thin basement membrane disease: a case report. BMC Nephrol (2015) 0.75
Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity. Int Urol Nephrol (2017) 0.75
Warfarin-related nephropathy in a patient with renal pelvic cancer. Clin Nephrol Case Stud (2017) 0.75
Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis (2009) 2.21
Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol (2009) 2.13
Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol (2009) 1.95
Gas6, warfarin, and kidney diseases. Clin Exp Nephrol (2004) 1.40
Warfarin-induced allergic interstitial nephritis and leucocytoclastic vasculitis. Intern Med J (2008) 1.34
An unusual cause of gross hematuria and transient ARF in an SLE patient with warfarin coagulopathy. Am J Kidney Dis (2004) 1.31
Thin basement membrane disease and acute renal failure secondary to gross hematuria and tubular necrosis. Am J Kidney Dis (2000) 1.31
Proposed pathogenesis of idiopathic loin pain-hematuria syndrome. Am J Kidney Dis (2006) 1.18
A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol (2009) 1.10
Atheromatous disease of the thoracic aorta and systemic embolism. Clinical picture and therapeutic challenge. Z Kardiol (2004) 1.08
Loin pain-hematuria syndrome associated with thin glomerular basement membrane disease and hemorrhage into renal tubules. Kidney Int (1996) 0.96
The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science (2005) 17.00
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48
Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int (2011) 4.51
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med (2016) 2.83
Management of glomerular proteinuria: a commentary. J Am Soc Nephrol (2003) 2.59
Typing of amyloidosis in renal biopsies: diagnostic pitfalls. Arch Pathol Lab Med (2007) 2.50
Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol (2004) 2.49
Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol (2009) 2.45
HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A (2002) 2.31
A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis. JACC Cardiovasc Interv (2009) 2.30
Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis (2009) 2.21
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res (2010) 2.03
Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol (2005) 1.90
S-nitrosylating agents: a novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cells. Mol Pharmacol (2006) 1.79
A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies. Kidney Int (2011) 1.77
A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience. JACC Cardiovasc Interv (2009) 1.76
Activation of the Nrf2/antioxidant response pathway increases IL-8 expression. Eur J Immunol (2005) 1.74
Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol (2005) 1.73
Bifurcation coronary lesions treated with the "crush" technique: an intravascular ultrasound analysis. J Am Coll Cardiol (2005) 1.72
Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation (2004) 1.72
Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatology (Oxford) (2011) 1.70
Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol (2007) 1.63
End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol (2014) 1.62
Treatment of coronary artery perforations complicating percutaneous coronary intervention with a polytetrafluoroethylene-covered stent graft. Am J Cardiol (2006) 1.59
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell (2010) 1.58
Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol (2009) 1.57
Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success. Am J Nephrol (2012) 1.57
Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology. Am J Pathol (2006) 1.57
Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther (2009) 1.54
Biomarkers of lupus nephritis determined by serial urine proteomics. Kidney Int (2008) 1.51
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol (2006) 1.51
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol (2007) 1.49
Hidden conditional random fields. IEEE Trans Pattern Anal Mach Intell (2007) 1.48
Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int (2005) 1.40
Comparison of safety and efficacy between first and second generation of angio-seal closure devices in interventional patients. J Invasive Cardiol (2004) 1.39
Acute angiographic and clinical results of the NIR w/SOX stent. J Invasive Cardiol (2002) 1.39
The SIRIUS-DIRECT trial: a multi-center study of direct stenting using the sirolimus-eluting stent in patients with de novo native coronary artery lesions. Catheter Cardiovasc Interv (2007) 1.38
Whole-genome plasticity among Mycobacterium avium subspecies: insights from comparative genomic hybridizations. J Bacteriol (2006) 1.33
Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum (2012) 1.32
An unusual cause of gross hematuria and transient ARF in an SLE patient with warfarin coagulopathy. Am J Kidney Dis (2004) 1.31
Staphylococcus infection-associated glomerulonephritis mimicking IgA nephropathy. Clin J Am Soc Nephrol (2006) 1.26
Free fatty acid-induced reduction in glucose-stimulated insulin secretion: evidence for a role of oxidative stress in vitro and in vivo. Diabetes (2007) 1.26
A dinucleotide deletion in CD24 confers protection against autoimmune diseases. PLoS Genet (2007) 1.25
Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice? Clin J Am Soc Nephrol (2012) 1.25
A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. Kidney Int (2009) 1.24
Proliferative glomerulonephritis with monoclonal IgG deposits recurs or may develop de novo in kidney allografts. Am J Kidney Dis (2011) 1.20
Proposed pathogenesis of idiopathic loin pain-hematuria syndrome. Am J Kidney Dis (2006) 1.18
Optimizing ACE-inhibitor therapy for chronic kidney disease. N Engl J Med (2006) 1.18
Biomarker discovery in human SLE nephritis. Bull NYU Hosp Jt Dis (2007) 1.18
Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation. J Am Soc Nephrol (2011) 1.17
Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes. Circulation (2003) 1.16
The intricate role of complement component C4 in human systemic lupus erythematosus. Curr Dir Autoimmun (2004) 1.15
A functional annotation of subproteomes in human plasma. Proteomics (2005) 1.15
Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus. Proc Natl Acad Sci U S A (2007) 1.13
Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis (2006) 1.12
IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression. Mod Pathol (2013) 1.10
Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology. Neoplasia (2012) 1.10
Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies. Hum Immunol (2006) 1.10
TGF-beta1 stimulates HO-1 via the p38 mitogen-activated protein kinase in A549 pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol (2002) 1.09
Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol (2015) 1.09
Intravascular ultrasound study of patterns of calcium in ruptured coronary plaques. Am J Cardiol (2005) 1.09
Comparison of economic and patient outcomes with minimally invasive versus traditional off-pump coronary artery bypass grafting techniques. Ann Surg (2008) 1.09
Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology (2010) 1.07